https://www.optimumcomms.com/wp-content/uploads/2024/04/Xeltis_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-13 17:53:352024-06-18 08:29:32Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXessTM, its restorative vascular access conduit
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-12 08:34:232024-06-12 08:35:23Climate resilient crops: Novo Nordisk Foundation and the Wellcome Trust award a grant of up to DKK 585 million to the ‘Ancient Environmental Genomics Initiative for Sustainability’
https://www.optimumcomms.com/wp-content/uploads/2023/02/Amberimplants_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-11 08:11:532024-06-11 08:11:53Amber Implants Completes Enrolment of First-In-Human Clinical Trial of its VCFix® Spinal System
https://www.optimumcomms.com/wp-content/uploads/2024/04/Template_Logo_300x180px-80x80Web_Logos-7.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-10 08:46:112024-06-10 10:16:07Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-10 08:42:122024-06-10 08:42:12Ariceum Therapeutics to Present Outstanding New Preclinical Data at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2024
https://www.optimumcomms.com/wp-content/uploads/2023/02/Alchemab_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-06 14:19:412024-06-06 14:19:41Alchemab advances a novel antibody with potential in Parkinson’s disease with support from The Michael J. Fox Foundation
https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-05 10:10:302024-06-05 10:10:30Vivet Therapeutics presents interim data on its Phase 1/2 GATEWAY trial for the Treatment of Wilson Disease at EASL Congress 2024
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-05 08:48:302024-06-05 08:48:30Resolution Therapeutics Announces New Breakthrough Clinical Data for Macrophage Cell Therapy in End Stage Liver Disease at EASL 2024
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-04 16:05:372024-06-04 16:05:37New innovative crops could significantly reduce agriculture’s climate change impact and environmental footprint
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-06-03 09:27:382024-06-03 09:27:38STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024
https://www.optimumcomms.com/wp-content/uploads/2023/12/Vesper_Bio_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-30 10:03:062024-05-30 12:05:31Vesper Bio announces completion of single ascending dose stage in trial of its lead candidate VES001, a potentially disease-modifying treatment for fronto-temporal dementia
https://www.optimumcomms.com/wp-content/uploads/2024/01/Vivet_Logo_300x180px-80x80-1.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-30 09:22:442024-05-30 09:22:44Study on Treatment of Wilson Disease in Japan Published in Japanese Journal of Gastroenterology and Hepatology
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-29 08:43:142024-05-29 08:43:14Resolution Therapeutics Announces Upcoming Scientific Presentations at EASL Congress 2024
https://www.optimumcomms.com/wp-content/uploads/2023/06/adcendo_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-29 08:09:252024-05-29 08:09:25Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-28 12:30:312024-05-29 09:04:06Novo Holdings portfolio company Numab Therapeutics announces Johnson & Johnson (‘J&J’) to acquire its wholly-owned subsidiary Yellow Jersey Therapeutics
https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-28 10:33:352024-05-28 10:33:35Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-28 09:00:032024-05-28 09:00:03Resolution Therapeutics to Participate in the Jefferies Global Healthcare Conference
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-24 08:41:502024-05-24 08:41:50STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-23 14:17:122024-05-23 14:17:12Novo Holdings Boston office named a 2024 Best Place to Work by the Boston Business Journal
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-05-23 10:30:112024-05-23 10:30:11Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024For more information about Optimum Strategic Communications, please get in touch.
